AgomAb Therapeutics (NASDAQ:AGMB – Get Free Report) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a report released on Tuesday.
AgomAb Therapeutics Stock Performance
Shares of AGMB stock opened at $14.70 on Tuesday. AgomAb Therapeutics has a 12 month low of $12.66 and a 12 month high of $16.65.
AgomAb Therapeutics Company Profile
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Featured Articles
- Five stocks we like better than AgomAb Therapeutics
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
